Advertisement

Topics

BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection

04:22 EDT 19 Oct 2016 | Reuters

* Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus (HDV) infection

Original Article: BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection

NEXT ARTICLE

More From BioPortfolio on "BRIEF-Eiger announces first patient dosed in phase 2 study of pegylated interferon lambda in hepatitis D virus infection"

Quick Search
Advertisement
 

Relevant Topic

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...